Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs in Advanced Glaucoma
NCT02330978Phase 1Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in primary open-angle glaucoma (POAG), sponsored by Universidade de São Paulo. Primary endpoint: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) at 6 months. Started Jan 2014; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT02330978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02330978.